• Vinicius Lins Ferreira, BorbaHelena Hiemisch LoboHHLUniversidade Federal do Paraná, Programa de Pós-Graduação em Ciências Farmacêuticas, Curitiba, PR, Brazil., Astrid Wiens, Maria Lucia Alves Pedroso, Vanessa Ferreira de Camargo Radunz, Cláudia Alexandra Pontes Ivantes, Aline Satie Oba Kuniyoshi, and Roberto Pontarolo.
• Universidade Federal do Paraná, Programa de Pós-Graduação em Ciências Farmacêuticas, Curitiba, PR, Brazil.
• Braz J Infect Dis. 2018 May 1; 22 (3): 186-192.

BackgroundThis study aimed to evaluate the clinical effectiveness in terms of sustained virological response and tolerability of available second generation direct-acting antivirals in Brazilian patients.MethodsThis was a retrospective observational study conducted in six centers in Southern Brazil. The sample comprised adult patients who were chronically infected with hepatitis C virus, regardless of virus genotype, fibrosis stage, or prior treatment. Statistical analysis was performed to compare the effectiveness among the treatments, and also to uncover the factors influencing the achievement of sustained virological response.ResultsA total of 296 patients were included in the study, with the majority receiving sofosbuvir with daclatasvir (59%) or sofosbuvir with simeprevir (26%). Overall sustained virological response rates were approximately 91.6%. For genotype 1, sofosbuvir with daclatasvir had an sustained virological response rate of approximately 95%, while the sustained virological response rate of sofosbuvir with simeprevir was 92%; this difference was statistically significant only for subtype 1b. The only treatment used for genotype 3 patients was sofosbuvir with daclatasvir, and lower rates of sustained virological response were observed for this group, compared to genotype 1 (84% versus 95%, p<0.05). Apart from this difference between genotypes, and a difference between patients who achieved rapid virologic response compared with those who did not, there were no other statistically significant factors associated with sustained virological response.ConclusionsThe results point to the effectiveness of second-generation direct-acting antivirals in hepatitis C virus Brazilian patients, especially those with genotype 1. Furthermore, that patients with genotype 3 need more attention and adjustments in available treatment options.Copyright © 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. All rights reserved.

34 keywords...

hide…